weight loss drug news today glp-1 october 2025 Rhode Island considers ending Medicaid coverage of drugs for • Rhode Island Current KFF Health News | Lots

The effects of semaglutide were consistent in those using renin-angiotensin system (RAS) blockers and SGLT2 inhibition compared with those not on these therapies

Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate

Together with Marit Westerterp, we reviewed the evidence on JAK inhibition, lipid changes, hematopoiesis, inflammation, and cardiovascular outcomes in IBD

Microdosing a GLP-1 (aka Ozempic, Wegovy, semaglutide, tirzepatide, zepbound, etc) is taking a lower than the lowest granular dose prescribed by the FDA for weight loss, but some people use it interchangeably when referring to one of the smaller doses on the dosing schedule

Vegetables and fiber Vegetables provide essential vitamins, minerals, and fiber but the way you prepare them matters, especially in the first weeks of treatment